MB-CART2019.1
Phase 2Cell therapy
MB-CART2019.1 is one of 57 biologic programs targeting Long-term Follow-up. It is currently in Phase 2.
3
Indications
4
Total Trials
3
Active Trials
56
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
145 competitors in Multiple Sclerosis
#DrugCompanyPhaseTrials
1Rinvoq
AbbViePhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Questran
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Frexalimab
SanofiPhase 3
Clemastine Fumarate
NovartisPhase 3
Activated Charcoal
SanofiPhase 3
Recombinant Zoster Vaccine
MMAXVAX Biotechnology Limited Liability Company
Phase 3
MRI Contrast-Enhancing Agents
SanofiPhase 3
PBR06
UUniversity Hospital, Bordeaux
Phase 3
Flomax
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Long-term Follow-up1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MB-CART2019.1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 2[1]
- Company
- MMiltenyi Biomedicine GmbH